Ill. SUMMARY OF HISTORICAL INVESTMENT PERFORMANCE The Fund Managers’ long term track record in healthcare technology investing clearly establishes the team as one of the most successful in the venture capital industry over the last two decades. Over an 18 year period and across the portfolios of six distinct venture funds focused on healthcare technology investments, the Fund Managers have delivered net performance that has consistently outperformed venture industry benchmarks and relevant public equity market indices!>6, The Fund Managers’ track record is notable for the following reasons: e Performance has’ been consistently top-quartile since the mid-1990s: NLV-I, NLV-II and the healthcare technology portfolios in the Sprout Capital funds have invested over $1.6 billion in healthcare technology companies since 1995. Over this time, The Fund Managers’ returns have consistently exceeded Cambridge Associates’ top-quartile benchmarks for U.S. venture capital healthcare and/or U.S. total venture capital.1¢ e Exceeded relevant public equity indices by substantial margins on all realized funds: The Fund Managers invested $1.02 billion in the portfolios of healthcare technology investments in four Sprout Capital funds (Sprout Capital IX, L.P., Sprout Capital VIIL L.P., Sprout Capital VIL, L.P. and Sprout Growth IL, L.P.), and these are now fully realized (or near fully realized in the case of Sprout Capital IX). The net annual IRR’s on these four funds outperformed the S&P 500 (568 - 2,259 bps), S&P Healthcare (302 - 2,066 bps), NASDAQ Composite (451 - 2,125 bps), and the Russell 3000 (502 - 2,215 bps) using the Public Market Equivalent Plus (PME+) methodology!”. Although PME+ methodology is most informative when used to analyze funds whose returns are mature, the PME+ methodology shows that NLV-I is outperforming these same indices, and shows encouraging results for NLV-II despite its relative immaturity. It is this consistently high level of return over an 18 year p